TROPION-Lung01 Study Design and Baseline demographics
Daiichi-Sankyo
Interim Overall Survival: ITT
100
80
Median (95% CI),
monthsa
HR
Dato-DXd
12.4 (10.8-14.8)
Docetaxel
11.0 (9.8-12.5)
0.90 (0.72-1.13)
OS probability, %
60-
40
40
20
20
+ Censored
2
4
60
10
12
14
16
18
20
20
22
Time since randomization, months
No. at risk
Dato-DXd
299
273
243
201
166
121
85
56
Docetaxel 305
273
239
193
156
115
76
42
32
33
14
6
29
13
4
Non-squamous HR (95% CI): 0.77 (0.59-1.01); Squamous HR (95% CI): 1.32 (0.87-2.00)
Trial is continuing to final OS analysis
HR, hazard ratio; ITT, intention to treat, OS, overall survival.
*Median OS follow-up was 11.8 (95% CI, 11.3-12.7) and 11.7 (95% CI, 10.9-12.9) months for Dato-DXd and docetaxel, respectively.
Information fraction
at interim analysis
(events/total events
required): 74%.
12View entire presentation